What a Compounded Pharmaceutical Dose Should Inspire: A Vote of Confidence
Acquiring expertise on proper aseptic processes that significantly enhance the quality of your compounding practices and the safety of your CSPs.
A Moment in Derby, UK:
The experience that sparked the question.
Last September, International Medical Industries (IMI) visited Derby, United Kingdom, to participate in an educational and networking event sponsored by Aseptic Medical Devices (AMD), a distributor serving the UK healthcare market.
The event brought together healthcare professionals from the United Kingdom and the United States, including pharmacists, pharmacy technicians, microbiologists, and members of AMD’s sales organization.
Throughout the gathering, the atmosphere was charged with a genuine desire to collaborate, exchange experiences, and better understand the challenges affecting two distant yet remarkably similar professional environments.
One particularly interesting observation emerged from the discussions surrounding tamper-evident technology.
While drug diversion prevention frequently dominates conversations about tamper-evident closures in the United States, the discussions in Derby placed considerable emphasis on something more fundamental: product protection and integrity.
That distinction raises an important question.
Isn’t product protection one of the foundations of diversion prevention?
After all, protecting the integrity of a medication container is an essential part of safeguarding its contents against unauthorized access, intentional adulteration, and other potential threats.
For hospital pharmacies, the responsibility to protect a compounded sterile preparation (CSP) should not end when the final label is applied. It should extend through storage, transportation, and every subsequent handoff until the medication reaches the patient.
What Should a Compounded Dose Inspire?
The professional investment behind every preparation.
The use of adhesive port seals and tapes has become a familiar practice in healthcare. These products have been used for decades to identify medication admixtures and provide some degree of protection to access ports.
However, familiarity with a practice should never be confused with assurance of its effectiveness.
Conventional adhesive seals may loosen, detach, or, depending on their design, be removed and reapplied without leaving unmistakable evidence of access. The presence of a seal does not necessarily establish that a medication container has remained undisturbed.
Consider the preparation of a seemingly uncomplicated 100-mL IV admixture from a powdered medication.
From component selection and verification to reconstitution, dilution, labeling, final inspection, and dispensing, the process involves numerous steps requiring technical skills, professional judgment, and adherence to established quality standards.
Whether a pharmacy compounds one dose or ten, each preparation represents an investment in personnel, training, materials, and quality assurance.
Few experiences are more frustrating for a sterile compounding technician than having to remake a preparation because it was damaged, compromised, or lost after leaving the cleanroom.
Yet the consequences extend beyond wasted time and materials. An unnecessarily repeated preparation consumes limited resources and can potentially delay patient therapy.
There is another consideration.
Hospital pharmacies increasingly rely on outsourced sterile preparations, often expecting the finished product to arrive with recognizable safeguards protecting its integrity.
Why should a preparation compounded within the hospital deserve a lesser expectation of protection?
Although compounded and conventionally manufactured products operate under different regulatory frameworks, the fundamental commitment to delivering a safe, appropriately protected medication should remain consistent.
A compounded dose deserves protection commensurate with the professional effort invested in preparing it.
The Journey Does Not End at the Cleanroom Door
The vulnerable interval between preparation and administration.
A completed CSP rarely travels directly from the compounding area to the patient.
Instead, it may pass through pharmacy storage, medication carts, pneumatic tube systems, automated dispensing cabinets, and various patient-care areas before administration.
Each transfer introduces another opportunity for mishandling, accidental damage, or unauthorized access.
The preparation may be technically flawless when it leaves the cleanroom, yet its subsequent handling can affect the confidence of the healthcare professional receiving it.
The pharmacy’s responsibility includes selecting appropriate packaging and establishing safe distribution procedures. Once the medication enters the patient-care environment, that responsibility becomes part of a broader institutional commitment shared by pharmacy, nursing, and other healthcare professionals.
USP <797> recognizes that special packaging, including tamper-evident closures, may be needed to help protect the quality of CSPs during shipping and transport. This is a consideration, not a universal requirement to use a particular type of closure. [1]
This is precisely where effective tamper-evident technology becomes valuable.
A properly selected closure can provide visible evidence that a protected access point may have been disturbed, allowing the receiving healthcare professional to recognize a potential problem before administration.
The objective is not simply to close a port.
The objective is to preserve confidence in the preparation throughout its journey to the patient.
When a Seal Looks Secure but Proves Little
The difference between covering an access point and revealing access.
Tamper-evident technology is hardly new.
Hospital pharmacists have recognized the value of protective closures for more than four decades. Indeed, early devices were developed to help identify possible access to prepared medications after they left pharmacy custody. [6]
Nevertheless, adhesive seals and tapes remain common in many compounding operations.
Their continued use raises a reasonable question:
If effective tamper-evident technology has existed for decades, why continue relying on closures that may be removed or displaced without leaving recognizable evidence?
Conventional adhesive seals often serve as visual indicators that an additive has been introduced into an IV container. However, indicating that a preparation has undergone compounding is not the same as establishing that its access port has remained protected.
A seal that can be lifted, repositioned, or replaced without visible damage may provide little assurance against undetected access.
This distinction is consistent with principles described by the US Food and Drug Administration (FDA) in its guidance on tamper-resistant packaging for certain over-the-counter medications. [2]
The FDA recognizes that conventional adhesive tape seals can be removed and reapplied without evidence of entry. It also acknowledges that specially engineered tapes and adhesives may overcome this limitation. [2]
Although this guidance does not establish packaging requirements for hospital CSPs, the underlying principle remains instructive.
Effective tamper evidence depends on the performance of the closure, not merely the presence of a seal.
Furthermore, an intact closure cannot independently guarantee the sterility, identity, or chemical integrity of a medication. These assurances depend on the entire compounding and medication-use process.
A tamper-evident closure serves a more specific purpose: providing recognizable evidence when a protected access point has been breached.
What Medication-Safety Guidance Actually Says
ISMP, diversion prevention, and product integrity.
The Institute for Safe Medication Practices (ISMP) has emphasized the importance of safeguarding medications throughout the medication-use process.
In its March 9, 2023, Medication Safety Alert!, ISMP addressed controlled-substance diversion and recommended the use of tamper-evident packaging or tamper-evident tape when dispensing controlled substances. [3]
ISMP also recommended inspecting the integrity of controlled-substance packaging before administration and during patient handoffs. [3]
These recommendations reinforce two important principles: medications should be appropriately protected, and healthcare professionals should remain alert to evidence of compromised packaging.
However, the effectiveness of the selected tamper-evident mechanism deserves equal consideration.
Not all tapes, seals, or closures provide the same degree of protection or the same clarity of evidence when disturbed.
In earlier guidance concerning certain Carpuject syringes, ISMP also described the use of a secure tamper-evident cap and chain-of-custody precautions for pharmacy-prepared controlled-substance syringes. [4]
ASHP’s controlled-substance diversion guidelines likewise emphasize chain-of-custody controls and tamper-evident transport containers. Those recommendations address medication distribution safeguards, rather than establishing that any one individual port closure is required. [5]
Drug diversion is particularly concerning because it may involve more than the unauthorized removal of medication.
In some instances, diversion has involved replacing or diluting the original medication with another substance, potentially exposing patients to ineffective treatment, contamination, or other serious harm.
Tamper-evident technology cannot eliminate diversion, but an appropriately designed closure can introduce an additional safeguard against undetected access.
The same principle deserves consideration beyond controlled substances.
Noncontrolled medications, including antibiotics, electrolytes, and other compounded sterile preparations, also warrant protection from unauthorized access and accidental compromise.
A strong medication safety culture should not reserve meaningful packaging safeguards exclusively for narcotics.
Product integrity is an essential component of medication safety, regardless of the drug’s controlled-substance classification.
Why Engineered Tamper Evidence Deserves Consideration
A commitment to product protection and confidence.
A carefully engineered, container-compatible solid port cap offers an important advantage over conventional adhesive seals: it can provide recognizable physical evidence when someone attempts to remove or breach the closure.
Rather than relying solely on adhesive contact with the container, these devices incorporate mechanical features designed to make removal or unauthorized access detectable.
For the receiving healthcare professional, that distinction can make a meaningful difference.
The objective is not to make a medication container absolutely tamper-proof—an unrealistic expectation for any packaging system—but to make attempted access more readily apparent.
International Medical Industries has a longstanding history of pioneering tamper-evident technology for secure medication delivery. Dating back to the 1980s, IMI’s early innovations such as the release of their Tamper Evident Caps helped advance medication security beyond traditional methods by introducing purpose-built solutions designed to provide visible evidence of tampering. Building on this foundation, IMI has continued to invest in intellectual property, advancing its technology through successive product improvements and additions informed by evolving clinical practices and customer needs.
That early innovation reflected a recognition of a challenge that remains relevant today: once a medication leaves the pharmacy, how can the next healthcare professional determine whether its protected access point has been disturbed?
Nearly four decades later, IMI continues to address this challenge through its Prep-Lock® family of tamper-evident devices, including closures designed for compatible IV syringes and IV bag additive ports. [7]
These products are engineered to provide a physical indication of possible tampering while supporting the medication preparation and distribution processes used by hospital pharmacies and other compounding facilities. [7]
Of course, appropriate product selection remains essential. Compatibility with the medication container, correct installation, and the ability of healthcare personnel to recognize evidence of compromise are critical considerations.
The value of an engineered closure lies not simply in its physical design but in the confidence it can inspire when used as part of a comprehensive medication protection strategy.
Ultimately, the question facing hospital pharmacy leaders is not whether their preparations already have a seal.
The more important question is whether that seal provides meaningful evidence that the medication’s protected access point has remained undisturbed.
Every compounded dose represents a commitment to quality, patient safety, and professional accountability.
That commitment deserves to extend beyond the cleanroom, through the medication distribution process, and to the point of administration.
A compounded pharmaceutical dose should inspire more than confidence in how it was prepared. It should inspire confidence in how it was protected.
And that confidence should never be based on appearance alone.
References
- United States Pharmacopeia. General Chapter <797>, Pharmaceutical Compounding—Sterile Preparations. USP–NF. 2023; §19.2, Packaging of CSPs. DOI: 10.31003/USPNF_M99925_07_01. View source
- U.S. Food and Drug Administration. Compliance Policy Guide Sec. 450.500: Tamper-Resistant Packaging Requirements for Certain Over-the-Counter Human Drug Products. May 1992. (FDA guidance concerning OTC products, not a hospital CSP mandate.) View source
- Institute for Safe Medication Practices (ISMP). Controlled substance drug diversion by healthcare workers as a threat to patient safety—Part II. ISMP Medication Safety Alert! Acute Care. 2023;28(5):1–5, especially p. 3. View source
- ISMP. Handling potentially flawed Carpuject syringes. ISMP Medication Safety Alert! Acute Care. May 31, 2018;23(11):1, 4. View source
- Clark J, et al. ASHP Guidelines on Preventing Diversion of Controlled Substances. American Journal of Health-System Pharmacy. 2022;79(24):2279–2306. doi:10.1093/ajhp/zxac246. View source
- International Medical Industries. Prep-Lock™ Tamper Evident Additive Port Caps (manufacturer product information); see also Prep-Lock™ Tamper Evident Caps for IV Syringes. View source
AI-Assistance Disclosure
This article is based on the author’s original professional observations, opinions, and experience. AI-assisted tools were used to support background research, organization, editorial drafting, and language review. The ideas and conclusions are the author’s own, and the manuscript is submitted for the author’s and IMI’s final editorial review and approval.
Seven97 Training Insight
Released July 2026
About the Author
Luis Hernandez, RPh, BCSCP, is a certified sterile compounding pharmacist and the founder of Seven97 Training Solutions. Dedicated to advancing USP 797 pharmaceutical training, validation, and certification, Luis aims to promote and inspire excellence in aseptic processing, medication and patient safety, and regulatory compliance.